DBV Technologies SA (DBVT)
0.469
-0.02
(-3.91%)
USD |
NASDAQ |
Nov 22, 16:00
0.4662
0.00 (0.00%)
After-Hours: 20:00
DBV Technologies Cash from Operations (Quarterly): -22.46M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -22.46M |
| June 30, 2024 | -35.07M |
| March 31, 2024 | -34.69M |
| December 31, 2023 | -13.69M |
| September 30, 2023 | -19.57M |
| June 30, 2023 | -25.55M |
| March 31, 2023 | -20.84M |
| December 31, 2022 | -23.88M |
| September 30, 2022 | -20.05M |
| June 30, 2022 | -10.25M |
| Date | Value |
|---|---|
| March 31, 2022 | -1.483M |
| December 31, 2021 | -18.79M |
| September 30, 2021 | -22.95M |
| June 30, 2021 | -30.30M |
| March 31, 2021 | -36.20M |
| December 31, 2020 | -33.53M |
| September 30, 2020 | -42.23M |
| June 30, 2020 | -40.16M |
| March 31, 2020 | -49.68M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-49.68M
Minimum
Mar 2020
-1.483M
Maximum
Mar 2022
-26.39M
Average
-23.88M
Median
Dec 2022
Cash from Operations (Quarterly) Benchmarks
| Edap TMS SA | -5.573M |
| Genfit SA | -- |
| Cellectis SA | -5.829M |
| Adaptimmune Therapeutics PLC | -54.45M |
| Akari Therapeutics PLC | -1.49M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.109M |
| Cash from Financing (Quarterly) | 0.007M |
| Free Cash Flow | -108.72M |
| Free Cash Flow Per Share (Quarterly) | -0.2376 |
| Free Cash Flow Yield | -241.1% |